Bausch’s $7.4 billion refinancing addresses near-term maturities and ends a five-year-long spinoff effort. However, the operational picture hasn’t changed; it still faces the loss of exclusivity of its crown jewel drug and EBITDA generator, Xifaxan, in 2028, along with a $4 billion maturity wall. This transaction extends the runway but doesn’t change the restructuring risks…
On Thursday, April 10, join Octus at 10:00 a.m. EST / 3:00 p.m. BST for a discussion of how recently enacted U.S. and retaliatory tariffs have changed the global economy. The discussion will focus on arming credit market participants with the information they need to stay ahead of the curve.
